Russian Heart Failure Journal 2008year Heart failure in patients with type 2 diabetes mellitus: problems and solutions

To access this material please log in or register

Register Authorize

Heart failure in patients with type 2 diabetes mellitus: problems and solutions

Atroshchenko E. S.



Heart failure may be both a consequence and a predisposing factor of type 2 DM. Life prediction for patients with combination of these two comorbidities is extremely unfavorable, especially if CHF was induced by coronary heart disease (CHD). The risk of death due to cardiovascular events in DM is equal to that in CHD, and these two conditions are considered equivalent in this respect. Although a diabetic heart is characterized by LV diastolic dysfunction, risk of coronary death in patients is higher than in individuals with low EF. Treatment of patients with DM and CHD is based on compromises because virtually all antidiabetic drugs exert adverse effects on the myocardium. Drugs of choice include RAAS blockers, metformin and selective β-adrenoblockers.
  1. Kanters SD, Banga JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc Med. 1999; 4 (2):67–75.
  2. Vaur L, Gueret P, Lievre M et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care. 2003; 26 (3):855‑860.
  3. Domanski M, Krause-Steinrauf H, Deedwania P et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003; 42 (5):914‑922.
  4. De Groote P, Lamblin N, Mouquet F et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004; 25 (8):656‑662.
  5. Burke AP, Kolodgie FD, Farb A et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001; 103 (7):934‑940.
  6. Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339 (4):229‑234.
  7. Оганов Р. Г, Масленникова Г. Я. Смертность от сердечно-сосудистых других хронических неинфекционных заболеваний среди трудоспособного населения России. Кардиоваскулярная терапия и профилактика. 2002; 1 (3):4–8.
  8. Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000; 102 (6):611‑616.
  9. Ingebretsen CG, Moreau P, Hawelu-Johnson C, Ingebretsen WR Jr. Performance of diabetic rat hearts: effects of anoxia and increased work. Am J Physiol. 1980; 239 (5):H614-20.
  10. Savabi F, Kirsch A. Altered functional activity and anoxic tolerance in diabetic rat isolated atria. Arch Biochem Biophys. 1990; 279 (1):183‑187.
  11. Soläng L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J. 1999; 20 (11):789‑795.
  12. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation. 2002; 105 (15):1861–1870.
  13. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34 (1):29–34.
  14. Capes SE, Hunt D, Malberg K et al. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000; 355 (9206):773‑778.
  15. Бейтуганов А. А. Рылова А. К. Встречаемость СД 2 типа у больных ХСН. Журнал Сердечная недостаточность. 2005; 6 (3):114‑116.
  16. Laskey WK, Selzer F, Vlachos HA et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol. 2002; 90 (10):1062–1067.
  17. Löwell H, Köning W, Engell S et al. Impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of population-based myocardial register follow-up study. Diabetologia. 2000; 43 (2):218‑226.
  18. MacDonald MR, Petrie MC, Varyani F et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008; 29 (11):1377–1385.
  19. Brophy JM, Dagenais GR, McSherry F et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004; 116 (5):300‑304.
  20. Amato L, Paolisso G, Cacciatore F et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 1997; 23 (3):213‑218.
  21. Shindler DМ, Kostis JВ, Yusuf S et al. Diabetes mellitus a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996; 77 (11):1017–1020.
  22. Hogg K, Swedberg K, McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and Prognosis. J Am Coll Cardiol. 2004; 43 (3):317‑327.
  23. Avendano GF, Agarwal RK, Bashey RI et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes. 1999; 48 (7):1443–1447.
  24. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006; 114 (6):597‑605.
  25. McGavock JM, Lingvay I, Zib I et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007; 116 (10):1170–1175.
  26. Szczepaniak LS, Dobbins RL, Metzger GJ et al.Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003; 49 (3):417‑423.
  27. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003; 14 (3):281‑287.
  28. Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000; 97 (4):1784–1789.
  29. Diamant M, Lamb HJ, Groeneveld Y et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003; 42 (2):328‑335.
  30. Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006; 47 (10):1997–2004.
  31. Hambly RI, Sherman L, Mehta J, Aintablian A. Reappraisal of the role of the diabetic state in coronary artery disease. Chest. 1976; 70 (2):251‑257.
  32. Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications. 2001; 15 (1):44–54.
  33. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007; 115 (3):387‑397.
  34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352 (9131):837‑853.
  35. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103 (22):2668–2673.
  36. Karter AJ, Ahmed AT, Liu J et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005; 22 (8):986‑993.
  37. Smooke S, Horwich T. B, Fonarow G. C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005; 149 (1):168‑174.
  38. Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005; 111 (5):583‑590.
  39. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26 (11):3160–3167.
  40. Nesto RW, Bell D, Bonow RO et at. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003; 108 (23):2941–2948.
  41. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28 (1):88‑136.
  42. Eurich DT, Majumdar SR, McAlister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005; 28 (10):2345–2351.
  43. Misbin RI. Phenformin-associated lactic acidosis: pathogenesis and treatment. Ann Intern Med. 1977; 87 (5):591‑595.
  44. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (7258):405‑412.
  45. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29 (6):1220–1226.
  46. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin. 2004; 20 (3):359‑367.
  47. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006; 81 (6):796‑806.
  48. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003; 91 (12A):30H-37H.
  49. DeFronzo RA, Ferrannini E, Hendler R et al. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 1983; 32 (1):35–45.
  50. Мравян М. А., Калинин А. П. Патогенез артериальной гипертензии при сахарном диабете и побочные действия применяемых гипотензивных средств. Российский кардиологический журнал. 2001; 1:35–39.
  51. Anguita Sánchez M. Prevention and treatment of congestive heart failure in diabetic patients. Rev Esp Cardiol. 2002; 55 (10):1083–1087.
  52. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989; 298 (6681):1152–1157.
  53. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992; 1 (2):92‑101.
  54. Samuelsson O, Hedner T, Berglund G et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Göteborg, Sweden. Hum Hypertens. 1994; 8 (4):257‑263.
  55. Bakris GL, Fonseca V, Katholi RE et al. for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004; 292 (18):2227–2236.
  56. Ferrua S, Bobbio M, Catalano E et al. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail. 2005; 11 (8):590‑594.
  57. Гиляревский С. Р., Столярова Н. И., Новикова Ю. П. и др. Эффективность и безопасность применения карведилола и бисопролола при лечении хронической сердечной недостаточности у больных сахарным диабетом 2‑го типа Рациональная фармакотерапия сердечно-сосудистых заболеваний. / под ред. И. Е. Чазова и Ю. Н. Беленкова. – М.: «Литература», 2004. – Том VI, Глава 29, 19–26.
  58. Deedwania PC, Giles TD, Klibaner M et al. Efficacy, safety and tolerability of metoprolol CR / XL in patients with diabetes and  chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005; 149 (1):159‑167.
  59. Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003; 41 (9):1529–1538.
  60. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353 (9146):9–13.
  61. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. (COPERNICUS). N Engl J Med. 2001; 344 (22):1651–1658.
  62. Kamalesh M, Subramanian U, Sawada S et al. Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail. 2006; 8 (4):404‑408.
  63. Лапина Ю. В., Петрухина А. А., Нарусов О. Ю. и др. Эффективность и безопасность применения β-блокатора бисопролола в комплексном лечении больных с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Результаты исследования РЭМБО-СД ХСН. Кардиоваскулярная терапия и профилактика. 2008; 1 (4):45–53.
  64. Kerr D, MacDonald IA, Heller SR, Tattersall RB. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol. 1990; 29 (6):685‑693.
  65. Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens. 2005; 18 (5 Pt 1):731‑737.
  66. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004; 110 (17):2618–2626.
  67. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345 (23):1667–1675.
  68. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355 (9200):253‑259.
  69. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345 (12):861‑869.
  70. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359 (9311):995‑1003.
  71. Атрощенко Е. С. Больной с сочетанной хронической сердечной и почечной недостаточностью: проблемы и решения Медицинские Новости. 2007; 10:11–15.
  72. Атрощенко Е. С., Атрощенко И. Е. Применение ингибиторов ангиотензин-превращающего фермента у кардиологических больных с дисфункцией почек: 30 лет спустя. Мед. новости. 2008; 4:34–36.
  73. O’Keefe JH, Wetzel M, Moe RR et al. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol. 2001; 37 (1):1–8.
  74. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998; 97 (1):48–54.
  75. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342 (3):145‑153.
  76. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 1998; 351 (9118):1755–1762.
  77. O’Keefe JH Jr, Miles JM, Harris WH et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999; 74 (2):171‑180.
  78. Lonn EM, Yusuf S, Jha P et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994; 90 (4):2056–2069.
  79. Kjøller-Hansen L, Steffensen R, Grande P. Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES). Am Heart J. 2004; 148 (3):475‑480.
  80. Oostera M, Voors A, Veeger N et al. for the QUO VADIS Study Investigators. QUO VADIS (effects of QUinapril On Vascular ACE And Determinants of Ischemia) Circulation. 1998; 98 (Suppl I):I-636.
  81. Lever AF, Beevers DG, Hole DJ et al. Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? Clin Exp Hypertens. 1999; 21 (5–6):553‑562.
  82. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353 (9153):611‑616.
  83. Атрощенко Е. С., Атрощенко И. Е. Программа ADVANCE – шаг вперед в профилактике сердечно-сосудистых заболеваний у больных с сахарным диабетом 2‑го типа. Мед. новости. 2008; 6:16–18.
  84. Maggioni AP, Latini R. How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI. Am Heart J. 1999; 138 (2 Pt 2):S183-187.
  85. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342 (8875):821‑828.
  86. Spargias KS, Lindsay SJ, Hall AS et al. Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure. Am J Cardiol. 1999; 83 (6):969‑71, A10.
  87. Dominguez LJ, Barbagallo M, Kattah W et al. Quinapril reduces microalbuminuria in essential hypertensive subjects. Am J Hypertens. 1995; 8 (8):808‑814.
  88. Larochelly P. Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group. Am J Hypertens. 1996; 9 (6):551‑559.
  89. Атрощенко Е. С. Дисфункция эндотелия у больных коронарной болезнью сердца: роль ингибиторов ангиотензин-превращающего фермента. Рецепт. 2008; 2 (58):123‑126.

To access this material please log in or register

Register Authorize
Ru En